by Raynovich Rod | Apr 29, 2019 | Biopharmaceuticals
Large Cap Biopharma Stocks: Performance and Valuations for 2019. In 2019 the IBB was a less risky pick for a biopharma portfolio; ABBV and BMY look good. Merck (MRK) and Vertex (VRTX) were the top winners since 1/15/18. There was a severe correction in biopharma...
by Raynovich Rod | Apr 7, 2019 | Biopharmaceuticals
4/11 ALERT: Need to check out reasons for biotech sell-off; could be proposed drug pricing bills and “affordability board.” See STAT News . See 4/11 chart below for XBI. Choppy pattern returns at resistance with no breakthrough highs. Biopharma stocks...
by Raynovich Rod | Mar 17, 2019 | Biopharmaceuticals
ALERT 3/21/19…BIOGEN (BIIB) down 28% to $233 after dropping Alzheimer’s Disease late stage trial; another failed clinical stage drug in AD. (more later). IBB down 2.5%. ====== 3/20/19…a whipsaw day…Powell comes to market rescue with...
by Raynovich Rod | Oct 4, 2018 | Biopharmaceuticals, Macro
Update 10/5/18 Very Weak Technicals after Biotech Sell-Off NASDAQ market closed off the lows down 1.16% at 7788. Biotech ETF IBB down 1.15% just above 3 month support of 116. Biotech ETF XBI down 1.51% at 90.45 broke downtrend line and May support at 92. More losers...
by Raynovich Rod | May 14, 2018 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update: 5/17…Mini-Rally Continues With Help From ASCO Abstracts XBI hits $93.78 above April highs, up 5.32% over 5 days, 10.5% YTD. IBB at April highs at $107.59, up 3.62% over 5 days, up 0.77% YTD Many Mid-Caps are hot: BLUE, CRSP, EXEL, FOLD, LGND, LOXO. See...
by Raynovich Rod | May 1, 2018 | Biopharmaceuticals
5/3 Testing February bottom and 200 MA of ~$100 on IBB and ~$85 on XBI. Red screen day. 2PM EDT Dow near flat line. Need to look for major gap up. Another potential negative on the horizon: “Bold Action on Drug Pricing” by Sect’y HHS. 5/2 Biotech...
by Raynovich Rod | Aug 30, 2017 | Biopharmaceuticals
M&A Boosts Biotech Stocks For Third Day Gilead Sciences (GILD) and bluebird bio (BLUE) Both Soar Today Biotech Sector Back to 2017 Highs The prospect of more M&A boosts biotech stocks for a third day this week. The large cap based IBB was up 1.87% today and...
by Raynovich Rod | Jun 22, 2017 | Biopharmaceuticals
6/27/17 Red Screen Day: Sell-Off in Biotechs Possibly Due to Senate Delay in Healthcare Vote IBB down 1.54% at $314.80. Momentum stocks are weak; NASDAQ down 1.2%. Take profits on XBI trade at $78 range after 34% move YTD. Allow time for arm twisting by Republicans...
by Raynovich Rod | Jun 9, 2017 | Biopharmaceuticals
ASCO Update: Many Stocks Rallied on the News Over the Past Month ASCO Rally is Holding but Fails to Break Through to New 2017 Highs The stock performance of most companies with ASCO news is summarized below.Biotechnology stocks are driven by clinical and deal news so...
by Raynovich Rod | May 26, 2017 | Biopharmaceuticals
Biotech Fades with Profit Taking: Is the pre-ASCO Momentum Gone? Technicals Matter Drug Pricing Scrutiny Continues Biotechs faded today now that the rush of oncology drug news slowed down. NASDAQ retained momentum with the ETF leader QQQ up 19% YTD pulling ahead of...
